(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip confirmed on Friday.
The UK firm said the Artemis-008 phase III trial evaluating risvutatug rezetecan (ris-rez) in patients with advanced or relapsed small-cell lung cancer (SCLC)...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE